Tag: pharmaceuticals
-
Synthetic Bio Platform Finds Potential Superbug Antibiotic
Researchers at University of California in San Diego created a process for cloning synthetic gene clusters from marine bacteria that generate molecules with therapeutic potential, and produced an antibiotic candidate to treat previously drug-resistant infections. The team led by UC-San Diego oceanography and pharmacy professor Bradley Moore, published its findings yesterday online in the journal…
-
Cancer Organizations, Biotech Partner on Drug Discovery
Institute of Cancer Research and Cancer Research Technology in London, and the drug discovery company Nuevolution A/S in Copenhagen, are collaborating on identifying leads for new cancer treatments that act on a promising biological pathway. The agreement includes the option to co-develop therapies from candidates identified in the project, but financial aspects of the deal…
-
Trial Underway Testing Head-Neck Cancer Immunotherapy
Advaxis Inc., a biopharmaceutical company in Princeton, New Jersey, began dosing the first patient in clinical trial testing a therapy that harnesses the immune system to treat head and neck cancer caused by the human papillomavirus, or HPV. The therapy is designed as part of a therapy strategy that includes robotic surgery to remove the…
-
Drugs Found with Potential to Replace Traumatic Memories
Neuroscientists at Massachusetts Institute of Technology found a class of drug compounds, some of which are now in use, can erase fear-causing memories in lab mice, and thus could treat post-traumatic stress disorder. The team from the lab of Li-Huei Tsai in MIT’s Picower Institute for Learning and Memory published its findings today in the…
-
Trial Shows Gene Therapy Helps Treat Genetic Eye Disease
Researchers at University of Oxford in the U.K. report initial results of a clinical trial showing healthy genes injected into the retinas of patients with a rare inherited disease improved their vision after six months. Findings from the study led by Oxford eye surgeon Robert MacLaren are published in today’s online issue of the journal…
-
Regeneron, Geisinger Health to Partner on Genetic Sequencing
Regeneron Pharmaceuticals Inc. in Tarrytown, New York and Geisinger Health System, a health care provider in Pennsylvania, are studying genetic causes of disease among the 2.6 million residents in areas served by Geisinger’s facilities. Financial terms of the five-year agreement were not disclosed. Under the deal, Geisinger will collect blood specimens from 100,000 Geisinger patients…
-
Clinical Trial to Test Safety of MRSA Drug Candidate
Enanta Pharmaceuticals, a biotechnology company in Watertown, Massachusetts, is starting an early-stage clinical trial of an antibiotic to treat methicillin-resistant Staphylococcus aureus or MRSA infections. The drug, code-named EDP-788, is being developed under a contract with National Institute of Allergy and Infectious Diseases, part of National Institutes of Health. MRSA is a bacteria resistant to many…
-
MedImmune, Biotech to Partner on Cancer Immunotherapies
MedImmune in Gaithersburg, Maryland, the biologics division of pharmaceutical company AstraZeneca, and Immunocore Ltd. in Oxford, U.K. will develop cancer treatments that harness the body’s immune system, based on Immunocore’s technology. The deal will pay Immunocore, for each therapy program licensed by MedImmune, $20 million initially and another $300 million in milestone payments, as well…
-
Stem Cell Therapy Aids Patient with ALS, Myasthenia Gravis
BrainStorm Cell Therapeutics Inc., in New York and Israel, reports a patient with the neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and myasthenia gravis responded with improved motor and cognitive functions after stem cell treatments developed by the company. Researchers from Israeli medical centers and research institutes, and the Mayo Clinic in the U.S. report the…
-
U.S., Europe Pharma Industries Implement Trial Data Sharing
Pharmaceutical industry associations in the U.S. and Europe began implementing their agreement from this past summer to provide more access to data from clinical trials conducted by their member companies. One of those companies, Paris-based Sanofi, released its procedures today for accessing its clinical trial data. The new processes are a result of a set…